Pharma Capital

Neuren Pharmaceuticals granted ASX trading halt pending trial update

The halt will remain in place until Wednesday 22nd March 2017.
Neuren to update on trial

Neuren Pharmaceuticals (ASX:NEU) has been granted a trading halt by the ASX, with its shares placed in pre-open.

Neuren requested the halt pending details regarding Neuren’s Phase 2 clinical trial of trofinetide in Rett syndrome.

The halt will remain in place until the opening of trade on Wednesday 22nd March 2017, or earlier if an announcement is made to the market.

Register here to be notified of future NEU Company articles
View full NEU profile

Neuren Pharmaceuticals Timeline

View All

Related Articles

If UniBio’s plans come to fruition it won’t be too long before the company orchestrates a major adjustment to the food-chain.
generic pill and bottle shot to denote Alliance's products
The company has made the transition from a business capitalised at £90mln to company now worth around a quarter of a billion pounds - but has the market at large picked up on (and priced in) the transformation?

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.